Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Biokraft International: Information ahead of the extraordinary general meeting to be held on 27 March 2024

Scandinavian Biogas Fuels International
Download the release

On 26 February 2024, Biokraft International AB (publ), reg.no 556528-4733 ("Biokraft" or the "Company"), announced the intention to resolve on a rights issue to finance repurchase of its senior secured green bonds (the "Rights Issue"). Due to this, the Company convened an extraordinary general meeting to be held on 27 March 2024, to, among other things, authorise the board of directors to resolve on the Rights Issue. In connection with the announcement, it was stated that the subscription price in the intended Rights Issue was expected to be determined no later than one day before the extraordinary general meeting and be announced through a separate press release.

On 13 March 2024, 1Vision Biogas AB ("1Vision Biogas") announced the outcome of the mandatory cash tender offer, which 1Vision Biogas made to the shareholders in the Company on 2 February 2024 (the "Offer"). Following the Offer, the Offeror controls a total of 41,498,279 shares in Biokraft, corresponding to approximately 95.2 per cent of the total number of shares and votes in Biokraft. 1Vision Biogas has also requested compulsory redemption of the remaining shares in the Company in accordance with the Swedish Companies Act. In the light of that, on 22 March 2024 the board of directors of Biokraft resolved, in accordance with 1Vision Biogas' request, to apply for delisting of the Company's shares from Nasdaq First North Premier Growth Market.

1Vision Biogas has, ahead of the extraordinary general meeting on 27 March 2024, informed that they will attend the meeting and vote against the proposal to authorise the board of directors in Biokraft to resolve on the Rights Issue.

Based on the above, the Company will not determine and make publish any subscription price in the intended Rights Issue and thus the Rights Issue will not be conducted.

This information was submitted, through the care of the above contact person, for publication on 26 March 2024 at 21:00 CET.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.